The authors evaluated the five-year outcomes in low-risk patients undergoing isolated surgical aortic valve replacement (SAVR) or SAVR with concomitant procedures within the randomized PARTNER 3 trial. In the PARTNER 3 trial, 454 patients with severe, symptomatic, tricuspid aortic stenosis (AS) underwent surgery and were followed for five years.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Aortic Surgery
January 23, 2025
This study compared isolated primary bioprosthetic surgical aortic valve replacement (SAVR) with isolated redo surgical aortic valve replacement (rSAVR) due to structural valve deterioration (SVD).
January 23, 2025
In this article, the authors aimed to assess whether post-implant transcatheter aortic valve prosthesis multi-detector computed characteristics differ between patients with native tricuspid and bicuspid aortic valve stenosis, as well as the effect on valve performance and clinical outcomes.
January 23, 2025
This retrospective analysis examined trends and outcomes of aortic valve replacement in patients under the age of 65 with aortic stenosis from 2013 to 2021, focusing on transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR).
January 16, 2025
In this study-level meta-analysis of randomized controlled trials (RCTs) evaluating the effect of early aortic valve replacement (AVR) versus clinical surveillance (CS) in patients with asymptomatic severe aortic stenosis (AS), four RCTs were identified and included for analysis: AVATAR, RECOVERY, EARLY TAVR, EVOLVED.
December 27, 2024
This study evaluates the impact of antegrade stenting of the distal arch and proximal descending aorta in patients with acute type A aortic dissection (ATAAD) who underwent nontotal arch procedures. The analysis includes 733 nonsyndromic patients treated between 2005 and 2022, of whom 95 received antegrade stenting.
November 26, 2024
Neurohormonal modulation and afterload reduction are essential for treating heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), therapy with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT).
November 26, 2024
This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.
November 26, 2024
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes.
October 17, 2024
The AVATAR Trial addressed the question of when and how to treat asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function. In the current report, the authors present the extended follow-up.